Lotus Pharmaceutical Co., Ltd.

TWSE:1795 Rapport sur les actions

Capitalisation boursière : NT$70.9b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Lotus Pharmaceutical Croissance future

Future contrôle des critères 4/6

Lotus Pharmaceutical devrait augmenter ses bénéfices et ses revenus de 27.6% et de 14.8% par an respectivement, tandis que le BPA devrait croître de croître de 27.3% par an.

Informations clés

28.6%

Taux de croissance des bénéfices

28.3%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices17.2%
Taux de croissance des recettes15.5%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour03 Sep 2024

Mises à jour récentes de la croissance future

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Recent updates

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Jul 18
Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09
Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04
These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09
Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11
Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19
Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Prévisions de croissance des bénéfices et des revenus

TWSE:1795 - Estimations futures des analystes et données financières antérieures (TWD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202521,3606,1616,0166,6665
12/31/202418,4924,7714,3126,3654
6/30/202416,9334,0142,4554,071N/A
3/31/202416,6323,9481,7173,325N/A
12/31/202316,9584,106-1,6611,614N/A
9/30/202316,7103,873-9183,440N/A
6/30/202317,5274,707-1,2112,974N/A
3/31/202315,9953,769-8943,251N/A
12/31/202214,6333,0216503,719N/A
9/30/202214,2643,1051812,198N/A
6/30/202211,9321,374-2272,012N/A
3/31/202212,4861,401-1,892496N/A
12/31/202112,6491,403-1,496120N/A
9/30/202112,9771,470-1,029421N/A
6/30/202112,8061,400-1,18226N/A
3/31/202112,0191,3443711,447N/A
12/31/202010,7291,027-491,949N/A
9/30/202010,802848-5521,619N/A
6/30/20209,933769-8631,116N/A
3/31/20209,307519-980905N/A
12/31/20199,611663-686420N/A
9/30/20198,130596-523266N/A
6/30/20197,6934631691N/A
3/31/20197,27835939720N/A
12/31/20186,42999403797N/A
9/30/20186,53738401774N/A
6/30/20186,53519277657N/A
3/31/20186,477110N/A623N/A
12/31/20176,42422N/A591N/A
9/30/20176,072-171N/A696N/A
6/30/20175,897-252N/A965N/A
3/31/20175,913-270N/A1,186N/A
12/31/20165,903-134N/A1,233N/A
9/30/20165,89678N/A1,490N/A
6/30/20165,910126N/A1,378N/A
3/31/20165,653198N/A1,223N/A
12/31/20155,522104N/A1,078N/A
9/30/20154,712-102N/A436N/A
6/30/20153,879-204N/A-531N/A
3/31/20153,125-312N/A-886N/A
12/31/20142,310-442N/A-1,032N/A
9/30/20142,201-307N/A-1,310N/A
6/30/20142,152-269N/A-503N/A
3/31/20142,411-330N/A-379N/A
12/31/20132,092-143N/A-388N/A
9/30/20131,673-178N/A72N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 1795 ( 29.6% par an) est supérieure au taux d'épargne ( 1% ).

Bénéfices vs marché: Les bénéfices de 1795 ( 29.6% par an) devraient croître plus rapidement que le marché TW ( 18.7% par an).

Croissance élevée des bénéfices: Les bénéfices de 1795 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 1795 ( 14.8% par an) devrait croître plus rapidement que le marché TW ( 11.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 1795 ( 16.3% par an) devrait croître plus lentement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de 1795 devrait être élevé dans 3 ans


Découvrir les entreprises en croissance